Cas:568577-84-4 N-(4-ethylbenzyl)-N-methylamine manufacturer & supplier

Chemical Name:N-(4-ethylbenzyl)-N-methylamine

CAS.NO:568577-84-4

Synonyms:1-(4-Ethylphenyl)-N-methylmethanamine;N-(4-ethylbenzyl)-N-methylamine;Benzenemethanamine, 4-ethyl-N-methyl-

Molecular Formula:C₁₀H₁₅N

Molecular Weight:149.233

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:213.7±9.0 °C at 760 mmHg

Density:0.9±0.1 g/cm3

Index of Refraction:1.509

PSA:12.03000

Exact Mass:149.120453

LogP:2.51

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-(4-Ethylphenyl)-N-methylmethanamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzenemethanamine, 4-ethyl-N-methyl- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzenemethanamine, 4-ethyl-N-methyl- Use and application,1-(4-Ethylphenyl)-N-methylmethanamine technical grade,usp/ep/jp grade.

Related News: This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? N-(4-ethylbenzyl)-N-methylamine manufacturer One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. N-(4-ethylbenzyl)-N-methylamine supplier This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? N-(4-ethylbenzyl)-N-methylamine vendor In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of ��predictable�� clinical value for life-threatening diseases for which effective treatment is not immediately available. N-(4-ethylbenzyl)-N-methylamine factory This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?